

## Change of Directors Interest following Share Consolidation and Performance Rights Expiry

**Melbourne, Australia, 27 December 2023:** Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, "Company", "GTG"), a global leader in genomics-based tests in health, wellness and serious disease, lodges four (4) updated Appendix 3Y – Change of Directors Interest notice. Please see the Appendix 3Y's that follow.

The notices reflect the recent 100 to 1 ordinary share consolidation and the expiry of performance rights held by directors. The change in interests does not relate to any trading undertaken by directors.

-END-

Authorised for release by the board of directors of Genetic Technologies Limited.

### Enquiries

#### Investor Relations

Adrian Mulcahy  
Automic Markets  
M: +61 438 630 411  
E: [adrian.mulcahy@automicgroup.com.au](mailto:adrian.mulcahy@automicgroup.com.au)

#### About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit [www.genetype.com](http://www.genetype.com)

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: Genetic Technologies Limited</b>
<b>ABN: 17 009 212 328</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Peter Irwin Rubenstein
<b>Date of last notice</b>	9 November 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Irwin Biotech Nominees Pty Ltd <BIO A/C> & RIP Opportunities Pty Ltd <PIR Super Fund A/C>
<b>Date of change</b>	18 December 2023 – Ordinary shares 21 December 2023 – Performance Rights

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<p><b>Irwin Biotech Nominees Pty Ltd &lt;BIO A/C&gt;</b>  87,049,310 Ordinary shares</p> <p><b>Irwin Biotech Nominees Pty Ltd</b>  2,000,000 Ordinary shares  86,582,700 Ordinary shares (represented by  144,305 American Depositary Receipts)</p> <p><b>RIP Opportunities Pty Ltd</b>  7,500,000 Ordinary shares (represented by  12,500 American Depositary Receipts)</p> <p><b>RIP Opportunities Pty Ltd &lt;PIR Super Fund A/C&gt;</b>  124,999,999 Ordinary shares</p> <p>7,500,000 Class A Performance Rights  25,000,000 Class B Performance Rights  25,000,000 Class C Performance Rights</p>
<b>Class</b>	Ordinary shares and Performance Rights
<b>Number acquired</b>	Nil
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	<p><b>Irwin Biotech Nominees Pty Ltd &lt;BIO A/C&gt;</b>  870,494 Ordinary shares</p> <p><b>Irwin Biotech Nominees Pty Ltd</b>  20,000 Ordinary shares  865,827 Ordinary shares (represented by  28,861 American Depositary Receipts)</p> <p><b>RIP Opportunities Pty Ltd</b>  75,000 Ordinary shares (represented by 2,500  American Depositary Receipts)</p> <p><b>RIP Opportunities Pty Ltd &lt;PIR Super Fund A/C&gt;</b>  1,250,000 Ordinary shares</p>

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Ordinary shares – as result of a share consolidation on the basis 1 for every parcel of 100 shares held.  Performance Rights - Expired
---	--

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	No
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: Genetic Technologies Limited</b>
<b>ABN: 17 009 212 328</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Nicholas Burrows
<b>Date of last notice</b>	24 December 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	18 December 2023 – Ordinary shares 21 December 2023 – Performance Rights
<b>No. of securities held prior to change</b>	1,670,000 Ordinary shares  5,000,000 Performance Rights

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

<b>Class</b>	Ordinary shares and Performance Rights
<b>Number acquired</b>	Nil
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	16,700 Ordinary shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Ordinary shares – as result of a share consolidation on the basis 1 for every parcel of 100 shares held.  Performance Rights - Expired

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	No
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: Genetic Technologies Limited</b>
<b>ABN: 17 009 212 328</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Lindsay Wakefield
<b>Date of last notice</b>	11 January 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Wakko Enterprises Pty Ltd
<b>Date of change</b>	18 December 2023 – Ordinary shares 21 December 2023 – Performance Rights
<b>No. of securities held prior to change</b>	<b>Wakko Enterprises Pty Ltd</b> 9,418,104 Ordinary shares  <b>Wakko Investments Pty Ltd</b> 5,000,000 Performance Rights

+ See chapter 19 for defined terms.



## Appendix 3Y

### Change of Director's Interest Notice

---

<b>Class</b>	Ordinary shares and Performance Rights
<b>Number acquired</b>	Nil
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	<b>Wakko Enterprises Pty Ltd</b> 94,182 Ordinary shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Ordinary shares – as result of a share consolidation on the basis 1 for every parcel of 100 shares held.  Performance Rights - Expired

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	No
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: Genetic Technologies Limited</b>
<b>ABN: 17 009 212 328</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Jerzy Muchnicki
<b>Date of last notice</b>	2 February 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	MJGD Nominees Pty Ltd
<b>Date of change</b>	18 December 2023 – Ordinary shares 21 December 2023 – Performance rights
<b>No. of securities held prior to change</b>	<b>MJGD Nominees Pty Ltd</b> 210,436,756 Ordinary shares  <b>JGM Investment Group (The Muchnicki Family A/C)</b> 9,400,000 Ordinary shares  <b>MJGD Nominees Pty Ltd &lt;BSMI A/C&gt;</b> 4,849,129 Ordinary shares  7,500,000 Class A Performance Rights 25,000,000 Class B Performance Rights 25,000,000 Class C Performance Rights

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Class</b>	Ordinary shares (represented by American Depositary Receipts) and Performance Rights
<b>Number acquired</b>	Nil
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	<b>MJGD Nominees Pty Ltd</b> 2,104,368 Ordinary shares  <b>JGM Investment Group (The Muchnicki Family A/C)</b> 94,000 Ordinary shares  <b>MJGD Nominees Pty Ltd &lt;BSMI A/C&gt;</b> 48,492 Ordinary shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Ordinary shares – as result of a share consolidation on the basis 1 for every parcel of 100 shares held.  Performance Rights - Expired

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	No
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.